| 4 |
| Polar Capital Holdings Plc |
| 4.6M |
| $275.9M |
| +3.8% |
| 4.728% |
| 0.65% |
| 5 | DRIEHAUS CAPITAL MANAGEMENT LLC | 4.4M | $266.7M | -1.6% | 4.571% | 1.55% |
| 6 | Jupiter Topco LLC | 4.2M | $252.7M | — | 4.331% | 0.10% |
| 7 | JPMORGAN CHASE & CO | 2.6M | $157.4M | +36.1% | 2.708% | 0.01% |
| 8 | Capital International Investors | 2.4M | $142.5M | -11.7% | 2.443% | 0.03% |
| 9 | STATE STREET CORP | 2.0M | $118.9M | +14.5% | 2.038% | 0.00% |
| 10 | TWO SIGMA INVESTMENTS, LP | 1.6M | $99.2M | +171.1% | 1.700% | 0.07% |
| 11 | DEERFIELD MANAGEMENT COMPANY, L.P. | 1.6M | $97.5M | 0.0% | 1.671% | 1.02% |
| 12 | Affinity Asset Advisors, LLC | 1.6M | $96.3M | -4.8% | 1.650% | 4.35% |
| 13 | WESTFIELD CAPITAL MANAGEMENT CO LP | 1.5M | $91.0M | +7.5% | 1.559% | 0.30% |
| 14 | ALLIANCEBERNSTEIN L.P. | 1.6M | $90.8M | +11.3% | 1.616% | 0.03% |
| 15 | CITADEL ADVISORS LLC | 1.4M | $87.4M | -49.8% | 1.498% | 0.00% |
| 16 | FRANKLIN TEMPLETON INC | 1.4M | $86.8M | +12.3% | 1.487% | 0.02% |
| 17 | WELLINGTON MANAGEMENT GROUP LLP | 1.4M | $86.0M | -70.5% | 1.475% | 0.01% |
| 18 | GEODE CAPITAL MANAGEMENT, LLC | 1.4M | $82.7M | +25.4% | 1.417% | 0.00% |
| 19 | Siren, L.L.C. | 1.3M | $79.6M | 0.0% | 1.364% | 1.61% |
| 20 | BNP Paribas Asset Management Holding S.A. | 1.3M | $77.9M | -3.8% | 1.335% | 0.08% |
| 21 | Pictet Asset Management Holding SA | 1.2M | $71.6M | +74.7% | 1.229% | 0.07% |
| 22 | BRAIDWELL LP | 1.1M | $68.3M | -15.5% | 1.171% | 2.53% |
| 23 | Nuveen, LLC | 993K | $59.9M | +297.2% | 1.027% | 0.01% |
| 24 | Invesco Ltd. | 903K | $54.5M | +1428.6% | 0.935% | 0.00% |
| 25 | ORBIMED ADVISORS LLC | 892K | $53.9M | -15.8% | 0.923% | 1.00% |
denotes a marquee investor (Buffett, Burry, ARK, Tiger Global, Pershing Square, Baupost and other widely-followed managers). “% of Fund” shows how much of that investor’s total 13F portfolio is invested in XENE — a direct measure of their conviction.
Institutions that fully closed their XENE position in Q2 2026
| 99.25% |
| 0.27 pp |
| $2.46B |
| 13% |
| Q4 2024 | 208 | +5.1% | 99.52% | +1.60 pp | $2.83B | +2.3% |
| Q3 2024 | 198 | — | 97.92% | — | $2.77B | — |
Source: SEC 13F institutional filings. Ownership % requires market cap data and will show once linked. Δ columns compare to the immediately prior filed quarter.
44 institutions opened new positions in XENE during Q2 2026, while 22 fully exited. 196 added to existing positions and 69 trimmed.
XENE institutional ownership fell by 2.23 percentage points quarter-over-quarter, with a net change of +23 holders.
The top 10 institutions account for 46.5% of all reported 13F value in XENE, and the top 25 account for 66.9%.
All data is sourced from SEC Form 13F filings, which institutional investment managers with at least $100M in assets are required to file each quarter. We process every 13F filing from EDGAR and recompute the aggregates after each cycle. Insider transactions are sourced from Form 4 filings.
Xenon Pharmaceuticals Inc. (XENE) Institutional Ownership